Janssen Research & Development, LLC

Little Rock, Arkansas

OncologyPhase IIIListed · JNJ

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

What changed

Phase III trial registered: A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

1w agoTrial registeredJul 7, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
Study registered
Jul 6, 2026
Non-Muscle Invasive Bladder Neoplasms · APPROVED_FOR_MARKETING · sponsor: Janssen Research & Development, LLC · Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
ClinicalTrials.gov · NCT06877676 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Mar 3, 2026
Carcinoma, Non-Small-Cell Lung · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
ClinicalTrials.gov · NCT07227025 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jun 4, 2025
Leukemia, Myeloid, Acute · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
ClinicalTrials.gov · NCT06852222 (opens the source filing in a new tab)
Trial
PHASE3 registered
Apr 9, 2024
Non-Muscle Invasive Bladder Neoplasms · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
ClinicalTrials.gov · NCT06211764 (opens the source filing in a new tab)
Trial
PHASE3 registered
Apr 7, 2023
Acute Coronary Syndrome · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
ClinicalTrials.gov · NCT05754957 (opens the source filing in a new tab)
Trial
PHASE3 registered
Feb 15, 2023
Ischemic Stroke; Ischemic Attack, Transient · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
ClinicalTrials.gov · NCT05702034 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jan 19, 2022
Crohn Disease · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
ClinicalTrials.gov · NCT05197049 (opens the source filing in a new tab)
Trial
PHASE1 registered
Aug 31, 2021
Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
ClinicalTrials.gov · NCT04973566 (opens the source filing in a new tab)
Trial
Study registered
Sep 28, 2020
Dementia, Alzheimer Disease · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
ClinicalTrials.gov · NCT04571697 (opens the source filing in a new tab)
Trial
PHASE1 registered
Nov 20, 2017
Urinary Bladder Neoplasms · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
ClinicalTrials.gov · NCT03404791 (opens the source filing in a new tab)
Trial
PHASE3 registered
Aug 20, 2015
Depressive Disorder, Treatment-Resistant · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
ClinicalTrials.gov · NCT02422186 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 85%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.99{"reasons":["name similarity 100%","semantic similarity 85%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.98{"reasons":["name similarity 100%","semantic similarity 84%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase III trial registered: A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
1w agoTrial completedSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
6w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
Apr 2025Trial completedSource (opens the source filing in a new tab)
Study registered, no phase assigned: A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
Mar 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
Mar 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
Feb 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

Study registered

PHASE1/PHASE2 registered

PHASE3 registered

PHASE3 registered

PHASE3 registered

PHASE3 registered

PHASE3 registered

PHASE1 registered

Study registered

PHASE1 registered

PHASE3 registered